NOVOZYMES A/S/S (OTCMKTS:NVZMY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday, reports.

According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “

Separately, JPMorgan Chase & Co. lowered NOVOZYMES A/S/S from a “neutral” rating to an “underweight” rating in a research report on Monday, September 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. NOVOZYMES A/S/S has an average rating of “Hold” and a consensus price target of $54.00.

NVZMY opened at $43.86 on Tuesday. The firm has a market cap of $12.83 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 2.05 and a beta of 0.75. The company has a current ratio of 1.27, a quick ratio of 0.75 and a debt-to-equity ratio of 0.05. NOVOZYMES A/S/S has a 12 month low of $39.96 and a 12 month high of $52.50. The stock has a fifty day moving average price of $42.41 and a 200-day moving average price of $45.37.

NOVOZYMES A/S/S (OTCMKTS:NVZMY) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.47 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by ($0.06). The company had revenue of $520.49 million during the quarter, compared to the consensus estimate of $556.19 million. NOVOZYMES A/S/S had a return on equity of 28.54% and a net margin of 22.31%. On average, equities research analysts forecast that NOVOZYMES A/S/S will post 1.69 EPS for the current year.


Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.

Read More: Analyst Ratings Trading

Get a free copy of the Zacks research report on NOVOZYMES A/S/S (NVZMY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with's FREE daily email newsletter.